Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?
When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.
5 Nov 00:00 · Zacks Investment Research
last updated on 5 Nov 15:22